糖ペプチド抗生物質の世界市場レポート 2025年

糖ペプチド抗生物質市場規模は、今後数年間で力強い成長が見込まれます。2029年にはCAGR9.5％で55億米ドルに成長します。予測期間の成長は、新興感染症、高齢者人口の増加、抗生物質耐性の継続的課題、研究開発投資とイノベーション、ヘルスケアインフラの拡大に起因します。予測期間の世界の動向には、抗生物質耐性の増加、研究開発の進展、需要を牽引する世界の健康上の緊急事態、抗生物質スチュワードシップのための共同研究、新興経済諸国における市場拡大などが含まれます。

がんと感染症の罹患率の増加が、今後数年間の糖ペプチド抗生物質市場の成長を牽引すると予想されます。一方、感染症は細菌、ウイルス、真菌、寄生虫などの生物によって引き起こされる病気です。糖ペプチド抗生物質は、メチシリン耐性黄色ブドウ球菌、レンサ球菌、腸球菌など、β-ラクタム系抗生物質やその他の抗生物質に耐性を持つ細菌に起因する様々な感染症の治療に使用されます。がん患者の場合、糖ペプチド抗生物質は、原発性がん細胞だけでなく、体内のさらに奥にある転移性細胞も標的にすることで、放射線治療の抗腫瘍効果を高めるのに役立ちます。例えば、米国を拠点とするがん撲滅のための非営利団体である米国がん協会によると、2022年の米国における新たながん罹患者数は190万人、がん関連死亡者数は60万9360人で、1日平均1670人が死亡しています。その結果、がんと感染症の症例数の増加が糖ペプチド抗生物質市場の成長を促進すると予想されます。

グラム陽性感染症の罹患率の増加は、今後数年間、グリコペプチド抗生物質市場の拡大を牽引する可能性が高いです。グラム陽性感染症は、黄色ブドウ球菌、肺炎球菌、化膿レンサ球菌などのグラム陽性菌によって引き起こされます。糖ペプチド抗生物質は、細菌の細胞壁形成を破壊する独自のメカニズムにより、多数のグラム陽性菌に対して特に有効です。例えば、英国の公衆衛生と感染症保護を担当する政府機関である英国健康安全保障庁（UK Health Security Agency）による「抗菌薬使用と耐性に関する英国サーベイランスプログラム（ESPAUR）」の2023年11月の報告では、2022年のA群溶血性レンサ球菌（iGAS）による感染症が2021年と比較して248％増加したことが指摘されています。さらに、2022年には3年前と比較してiGAS症例が21％多く記録され、グラム陽性感染症の有病率の上昇とグリコペプチド抗生物質市場への影響が浮き彫りになりました。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場：金利、インフレ、地政学、コロナ禍、回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界の糖ペプチド抗生物質PESTEL分析（政治、社会、技術、環境、法的要因、促進要因、制約）
• 最終用途産業の分析
• 世界の糖ペプチド抗生物質市場：成長率分析
• 世界の糖ペプチド抗生物質市場の実績：規模と成長, 2019-2024
• 世界の糖ペプチド抗生物質市場の予測：規模と成長, 2024-2029, 2034F
• 世界の糖ペプチド抗生物質総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界の糖ペプチド抗生物質市場：薬剤別、実績と予測, 2019-2024, 2024-2029F, 2034F
• バンコマイシン
• ダルババンシン
• オリタヴァンシン
• その他の薬剤
• 世界の糖ペプチド抗生物質市場：投与経路別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 経口
• パレンタル
• その他のルート
• 世界の糖ペプチド抗生物質市場：適応症別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 皮膚および構造感染症
• 髄膜炎
• クロストリディオイデス・ディフィシル感染症
• 腸炎
• その他の適応症
• 世界の糖ペプチド抗生物質市場：エンドユーザー別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院
• 専門クリニック
• ホームケア
• その他のエンドユーザー
• 世界の糖ペプチド抗生物質市場、バンコマイシンのサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• バンコマイシン注射
• バンコマイシン経口液
• バンコマイシンカプセル
• バンコマイシン溶液粉末
• 世界の糖ペプチド抗生物質市場、ダルババンシンのサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• ダルババンシンIV（静脈内）製剤
• 注射用ダルババンシン粉末
• 世界の糖ペプチド抗生物質市場、オリタバンシンのサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• オリタバンシンIV（静脈内）製剤
• 注射用オリタバンシン粉末
• 世界の糖ペプチド抗生物質市場、その他の医薬品のサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• テイコプラニン
• リネゾリド
• ダプトマイシン
• その他のグリコペプチドおよびリポグリコペプチド抗生物質

第7章 地域別・国別分析

• 世界の糖ペプチド抗生物質市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界の糖ペプチド抗生物質市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 糖ペプチド抗生物質市場：競合情勢
• 糖ペプチド抗生物質市場：企業プロファイル
  • ANI Pharmaceuticals Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Fresenius SE & Co. KGaA Overview, Products and Services, Strategy and Financial Analysis
  • Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Novartis AG Overview, Products and Services, Strategy and Financial Analysis
  • Hikma Pharmaceuticals Plc. Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Aurobindo Pharma Limited
• Abbvie Inc.
• Cumberland Pharmaceuticals Inc.
• Janssen Global
• Bristol-Myers Squibb Company
• Shenwei Pharmaceutical Hainan Co. Ltd.
• Zhejiang Hisun Pharmaceutical Co. Ltd.
• Alvogen
• Bayer AG
• Merck & Co. Inc.
• Teva Pharmaceutical Industries Ltd.
• Sanofi SA
• GlaxoSmithKline plc
• Johnson & Johnson
• AstraZeneca

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• 糖ペプチド抗生物質市場2029：新たな機会を提供する国
• 糖ペプチド抗生物質市場2029：新たな機会を提供するセグメント
• 糖ペプチド抗生物質市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Glycopeptide antibiotics constitute a category of antibiotics characterized by structures that include a glycosylated cyclic or polycyclic non-ribosomal peptide, and they are employed to impede the formation of bacterial cell walls. These antibiotics were initially discovered in plant and soil bacteria.

The primary drugs within the glycopeptide antibiotics class include vancomycin, dalbavancin, oritavancin, and others. Vancomycin, for example, is a member of the glycopeptide antibiotics family, recognized for its ability to eliminate microorganisms in the intestines. It is used in the treatment of colitis, a condition that can develop after antibiotic therapy. These drugs are administered through oral, parenteral, and other routes for the treatment of various conditions such as skin and structure infections, meningitis, Clostridioides difficile infection, enterocolitis, and more. The end-users of these antibiotics include hospitals, specialty clinics, home care, and other healthcare providers.

The glycopeptide antibiotics market research report is one of a series of new reports from The Business Research Company that provides glycopeptide antibiotics market statistics, including glycopeptide antibiotics industry global market size, regional shares, competitors with a glycopeptide antibiotics market share, detailed glycopeptide antibiotics market segments, market trends and opportunities, and any further data you may need to thrive in the glycopeptide antibiotics industry. This glycopeptide antibiotics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The glycopeptide antibiotics market size has grown strongly in recent years. It will grow from $3.54 billion in 2024 to $3.82 billion in 2025 at a compound annual growth rate (CAGR) of 8.0%. The growth in the historic period can be attributed to increasing antibiotic resistance, rising incidence of infectious diseases, government initiatives, increasing healthcare expenditure, globalization of infectious diseases.

The glycopeptide antibiotics market size is expected to see strong growth in the next few years. It will grow to $5.5 billion in 2029 at a compound annual growth rate (CAGR) of 9.5%. The growth in the forecast period can be attributed to emerging infectious diseases, increasing geriatric population, continued antibiotic resistance challenges, R&D investments and innovations, expansion of healthcare infrastructure. Major trends in the forecast period include increasing antibiotic resistance, advancements in research and development, global health emergencies driving demand, collaborations for antibiotic stewardship, market expansion in emerging economies.

The increasing incidence of cancer and infectious diseases is anticipated to drive the growth of the glycopeptide antibiotics market in the coming years. Cancer is a disease characterized by the uncontrolled multiplication of specific body cells that can spread to other regions, while infectious diseases are ailments caused by organisms such as bacteria, viruses, fungi, or parasites. Glycopeptide antibiotics are utilized to treat various infectious disorders resulting from methicillin-resistant Staphylococcus aureus, Streptococcus, or Enterococcus bacteria that are resistant to beta-lactams and other antibiotic classes. In cancer patients, glycopeptide antibiotics help enhance the antitumor effects of radiotherapy by targeting not only the primary cancer cells but also metastatic cells located further in the body. For example, the American Cancer Society, a US-based non-profit organization dedicated to cancer elimination, reported that in 2022, there were 1.9 million new cancer cases and 609,360 cancer-related deaths in the US, averaging 1,670 fatalities per day. Consequently, the rising cases of cancer and infectious diseases are expected to propel the growth of the glycopeptide antibiotics market.

The growing incidence of gram-positive infections is likely to drive the glycopeptide antibiotic market's expansion in the coming years. Gram-positive infections are caused by gram-positive bacteria, including Staphylococcus aureus, Streptococcus pneumoniae, and Streptococcus pyogenes, among others. Glycopeptide antibiotics are particularly effective against numerous gram-positive bacteria due to their unique mechanism, which disrupts bacterial cell wall formation. For instance, the November 2023 report from the English Surveillance Programme for Antimicrobial Utilization and Resistance (ESPAUR) by the UK Health Security Agency, a governmental body responsible for public health and infectious disease protection in England, noted a 248% increase in infections from Group A Streptococcus (iGAS) in 2022 compared to 2021. Additionally, there were 21% more iGAS cases recorded in 2022 compared to three years prior, highlighting the rising prevalence of gram-positive infections and its impact on the glycopeptide antibiotic market.

Product innovation is a significant trend gaining traction in the glycopeptide antibiotics market. Key players in this sector are concentrating on developing groundbreaking products to enhance their market positions. For example, in October 2022, Leiden University, a research institution in the Netherlands, discovered new variants of the antibiotic vancomycin. This new variant was created by attaching a group of molecules to the existing structure of vancomycin. The result is a variant that is up to a thousand times more effective against gram-positive bacteria compared to the original vancomycin and exhibits lower nephrotoxicity than commercially available polymyxin antibiotics. This innovation addresses the limitation of vancomycin, which is effective only against gram-positive strains and cannot penetrate the outer membrane of gram-negative bacteria.

Leading companies in the glycopeptide antibiotics market are pursuing strategic partnerships to introduce life-saving revolutionary antibiotics in the Middle East. Strategic partnerships involve companies leveraging each other's strengths and resources for mutual benefits and success. For instance, in March 2022, Cumberland Pharmaceuticals Inc., a US-based specialty pharmaceutical firm, announced a partnership with Tabuk Pharmaceutical Manufacturing Company. This agreement grants Tabuk exclusive trademark rights to promote the Vibativ (telavancin) injection for patients in Saudi Arabia, Jordan, and potentially other Middle Eastern countries. Vibativ is a crucial medication for patients suffering from ventilator-associated pneumonia and hospital-acquired pneumonia caused by various gram-positive bacterial infections, including those that are challenging to treat and multidrug-resistant. Tabuk Pharmaceutical Manufacturing Company is a pharmaceutical firm based in Saudi Arabia.

In January 2023, Fairlong Capital LLC, a US-based investment firm, acquired DoseMeRx for an undisclosed sum. This acquisition aims to enhance Fairlong Capital's precision dosing capabilities and improve patient outcomes through advanced medication management solutions. This strategic move allows the company to utilize innovative technology for more effective healthcare delivery. DoseMeRx is a US-based Bayesian dosing platform that optimizes dosing for glycopeptide antibiotics, such as vancomycin, by personalizing treatment based on individual patient factors.

Major companies operating in the glycopeptide antibiotics market include ANI Pharmaceuticals Inc., Fresenius SE & Co. KGaA, Pfizer Inc., Novartis AG, Hikma Pharmaceuticals Plc., Aurobindo Pharma Limited, Abbvie Inc., Cumberland Pharmaceuticals Inc., Janssen Global, Bristol-Myers Squibb Company, Shenwei Pharmaceutical Hainan Co. Ltd., Zhejiang Hisun Pharmaceutical Co. Ltd., Alvogen, Bayer AG, Merck & Co. Inc., Teva Pharmaceutical Industries Ltd., Sanofi SA, GlaxoSmithKline plc, Johnson & Johnson, AstraZeneca, Boehringer Ingelheim GmbH, Cipla Inc.

North America was the largest region in the glycopeptide antibiotics market in 2024. The regions covered in the glycopeptide antibiotics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the glycopeptide antibiotics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The glycopeptide antibiotics market consists of sales of teicoplanin, telavancin and ramoplanin. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Glycopeptide Antibiotics Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on glycopeptide antibiotics market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for glycopeptide antibiotics ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The glycopeptide antibiotics market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Drug: Vancomycin; Dalbavancin; Oritavancin; Other Drugs
• 2) By Route of Administration: Oral; Parenteral; Other Routes
• 3) By Indication: Skin And Structure Infection; Meningitis; Clostridioides Difficile Infection; Enterocolitis; Other Indications
• 4) By End-User: Hospitals; Specialty Clinics; Homecare; Other End-Users
• Subsemgents:
• 1) By Vancomycin: Vancomycin Injection; Vancomycin Oral Solution; Vancomycin Capsules; Vancomycin Powder for Solution
• 2) By Dalbavancin: Dalbavancin IV (Intravenous) Formulation; Dalbavancin Powder for Injection
• 3) By Oritavancin: Oritavancin IV (Intravenous) Formulation,Oritavancin Powder for Injection
• 4) By Other Drugs: Teicoplanin; Linezolid; Daptomycin; Other Glycopeptide and Lipoglycopeptide Antibiotics

• Companies Mentioned: ANI Pharmaceuticals Inc.; Fresenius SE & Co. KGaA; Pfizer Inc.; Novartis AG; Hikma Pharmaceuticals Plc.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Glycopeptide Antibiotics Market Characteristics

3. Glycopeptide Antibiotics Market Trends And Strategies

4. Glycopeptide Antibiotics Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global Glycopeptide Antibiotics Growth Analysis And Strategic Analysis Framework

• 5.1. Global Glycopeptide Antibiotics PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Glycopeptide Antibiotics Market Growth Rate Analysis
• 5.4. Global Glycopeptide Antibiotics Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Glycopeptide Antibiotics Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Glycopeptide Antibiotics Total Addressable Market (TAM)

6. Glycopeptide Antibiotics Market Segmentation

• 6.1. Global Glycopeptide Antibiotics Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Vancomycin
• Dalbavancin
• Oritavancin
• Other Drugs
• 6.2. Global Glycopeptide Antibiotics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Oral
• Parenteral
• Other Routes
• 6.3. Global Glycopeptide Antibiotics Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Skin And Structure Infection
• Meningitis
• Clostridioides Difficile Infection
• Enterocolitis
• Other Indications
• 6.4. Global Glycopeptide Antibiotics Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals
• Specialty Clinics
• Homecare
• Other End-Users
• 6.5. Global Glycopeptide Antibiotics Market, Sub-Segmentation Of Vancomycin, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Vancomycin Injection
• Vancomycin Oral Solution
• Vancomycin Capsules
• Vancomycin Powder for Solution
• 6.6. Global Glycopeptide Antibiotics Market, Sub-Segmentation Of Dalbavancin, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Dalbavancin IV (Intravenous) Formulation
• Dalbavancin Powder for Injection
• 6.7. Global Glycopeptide Antibiotics Market, Sub-Segmentation Of Oritavancin, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Oritavancin IV (Intravenous) Formulation
• Oritavancin Powder for Injection
• 6.8. Global Glycopeptide Antibiotics Market, Sub-Segmentation Of Other Drugs, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Teicoplanin
• Linezolid
• Daptomycin
• Other Glycopeptide and Lipoglycopeptide Antibiotics

7. Glycopeptide Antibiotics Market Regional And Country Analysis

• 7.1. Global Glycopeptide Antibiotics Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Glycopeptide Antibiotics Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Glycopeptide Antibiotics Market

• 8.1. Asia-Pacific Glycopeptide Antibiotics Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Glycopeptide Antibiotics Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Glycopeptide Antibiotics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Glycopeptide Antibiotics Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Glycopeptide Antibiotics Market

• 9.1. China Glycopeptide Antibiotics Market Overview
• 9.2. China Glycopeptide Antibiotics Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Glycopeptide Antibiotics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Glycopeptide Antibiotics Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Glycopeptide Antibiotics Market

• 10.1. India Glycopeptide Antibiotics Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Glycopeptide Antibiotics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Glycopeptide Antibiotics Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Glycopeptide Antibiotics Market

• 11.1. Japan Glycopeptide Antibiotics Market Overview
• 11.2. Japan Glycopeptide Antibiotics Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Glycopeptide Antibiotics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Glycopeptide Antibiotics Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Glycopeptide Antibiotics Market

• 12.1. Australia Glycopeptide Antibiotics Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Glycopeptide Antibiotics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Glycopeptide Antibiotics Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Glycopeptide Antibiotics Market

• 13.1. Indonesia Glycopeptide Antibiotics Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Glycopeptide Antibiotics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Glycopeptide Antibiotics Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Glycopeptide Antibiotics Market

• 14.1. South Korea Glycopeptide Antibiotics Market Overview
• 14.2. South Korea Glycopeptide Antibiotics Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Glycopeptide Antibiotics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Glycopeptide Antibiotics Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Glycopeptide Antibiotics Market

• 15.1. Western Europe Glycopeptide Antibiotics Market Overview
• 15.2. Western Europe Glycopeptide Antibiotics Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Glycopeptide Antibiotics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Glycopeptide Antibiotics Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Glycopeptide Antibiotics Market

• 16.1. UK Glycopeptide Antibiotics Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Glycopeptide Antibiotics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Glycopeptide Antibiotics Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Glycopeptide Antibiotics Market

• 17.1. Germany Glycopeptide Antibiotics Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Glycopeptide Antibiotics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Glycopeptide Antibiotics Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Glycopeptide Antibiotics Market

• 18.1. France Glycopeptide Antibiotics Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Glycopeptide Antibiotics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Glycopeptide Antibiotics Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Glycopeptide Antibiotics Market

• 19.1. Italy Glycopeptide Antibiotics Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Glycopeptide Antibiotics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Glycopeptide Antibiotics Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Glycopeptide Antibiotics Market

• 20.1. Spain Glycopeptide Antibiotics Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Glycopeptide Antibiotics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Glycopeptide Antibiotics Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Glycopeptide Antibiotics Market

• 21.1. Eastern Europe Glycopeptide Antibiotics Market Overview
• 21.2. Eastern Europe Glycopeptide Antibiotics Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Glycopeptide Antibiotics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Glycopeptide Antibiotics Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Glycopeptide Antibiotics Market

• 22.1. Russia Glycopeptide Antibiotics Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Glycopeptide Antibiotics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Glycopeptide Antibiotics Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Glycopeptide Antibiotics Market

• 23.1. North America Glycopeptide Antibiotics Market Overview
• 23.2. North America Glycopeptide Antibiotics Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Glycopeptide Antibiotics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Glycopeptide Antibiotics Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Glycopeptide Antibiotics Market

• 24.1. USA Glycopeptide Antibiotics Market Overview
• 24.2. USA Glycopeptide Antibiotics Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Glycopeptide Antibiotics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Glycopeptide Antibiotics Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Glycopeptide Antibiotics Market

• 25.1. Canada Glycopeptide Antibiotics Market Overview
• 25.2. Canada Glycopeptide Antibiotics Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Glycopeptide Antibiotics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Glycopeptide Antibiotics Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Glycopeptide Antibiotics Market

• 26.1. South America Glycopeptide Antibiotics Market Overview
• 26.2. South America Glycopeptide Antibiotics Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Glycopeptide Antibiotics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Glycopeptide Antibiotics Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Glycopeptide Antibiotics Market

• 27.1. Brazil Glycopeptide Antibiotics Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Glycopeptide Antibiotics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Glycopeptide Antibiotics Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Glycopeptide Antibiotics Market

• 28.1. Middle East Glycopeptide Antibiotics Market Overview
• 28.2. Middle East Glycopeptide Antibiotics Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Glycopeptide Antibiotics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Glycopeptide Antibiotics Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Glycopeptide Antibiotics Market

• 29.1. Africa Glycopeptide Antibiotics Market Overview
• 29.2. Africa Glycopeptide Antibiotics Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Glycopeptide Antibiotics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Glycopeptide Antibiotics Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Glycopeptide Antibiotics Market Competitive Landscape And Company Profiles

• 30.1. Glycopeptide Antibiotics Market Competitive Landscape
• 30.2. Glycopeptide Antibiotics Market Company Profiles
  • 30.2.1. ANI Pharmaceuticals Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Fresenius SE & Co. KGaA Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Novartis AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Hikma Pharmaceuticals Plc. Overview, Products and Services, Strategy and Financial Analysis

31. Glycopeptide Antibiotics Market Other Major And Innovative Companies

• 31.1. Aurobindo Pharma Limited
• 31.2. Abbvie Inc.
• 31.3. Cumberland Pharmaceuticals Inc.
• 31.4. Janssen Global
• 31.5. Bristol-Myers Squibb Company
• 31.6. Shenwei Pharmaceutical Hainan Co. Ltd.
• 31.7. Zhejiang Hisun Pharmaceutical Co. Ltd.
• 31.8. Alvogen
• 31.9. Bayer AG
• 31.10. Merck & Co. Inc.
• 31.11. Teva Pharmaceutical Industries Ltd.
• 31.12. Sanofi SA
• 31.13. GlaxoSmithKline plc
• 31.14. Johnson & Johnson
• 31.15. AstraZeneca

32. Global Glycopeptide Antibiotics Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Glycopeptide Antibiotics Market

34. Recent Developments In The Glycopeptide Antibiotics Market

35. Glycopeptide Antibiotics Market High Potential Countries, Segments and Strategies

• 35.1 Glycopeptide Antibiotics Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Glycopeptide Antibiotics Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Glycopeptide Antibiotics Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer